Neuroendocrine Neoplasm Clinical Trial
Official title:
A Phase II Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PM8002 Injection in Combination With Chemotherapy as Second Line Therapy in Unresectable Neuroendocrine Neoplasm
Verified date | May 2023 |
Source | Biotheus Inc. |
Contact | Jia Song |
Phone | +86 15921737659 |
song.j[@]biotheus.com | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study will evaluate the efficacy and safety of PM8002 in combination with FOLFIRI as second line treatment for neuroendocrine neoplasm (NEC and Ki-67≥55% G3 NET).
Status | Recruiting |
Enrollment | 60 |
Est. completion date | January 1, 2028 |
Est. primary completion date | January 1, 2027 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Signed informed consent form before any trial-related processes; 2. Aged = 18 years; 3. Ki-67=55% G3 NET and NEC were confirmed histologically or cytologically by pathological diagnosis in this study; 4. Subjects failed first-line platinum-based chemotherapy; 5. Adequate organ function; 6. The Eastern Cancer Cooperative Group (ECOG) performance score of 0 or 1; 7. Expected survival = 12 weeks; 8. Had at least one measurable tumor lesion according to RECIST v1.1; Exclusion Criteria: 1. History of severe allergic disease, severe drug allergy or have known allergy to any component of the study drugs; 2. Evidence and history of severe bleeding tendency; 3. History of severe cardiovascular diseases within 6 months; 4. Subjects should provide formalin-fixed-paraffin-embedded (FFPE) tumor samples during the screening period (up to 24 months); 5. Current presence of uncontrolled pleural, pericardial, and peritoneal effusions; 6. History of allogeneic hematopoietic stem cell transplantation or allogeneic organ transplantation; 7. History of alcohol abuse, psychotropic substance abuse or drug abuse; 8. Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome; 9. Pregnant or lactating women; 10. Other conditions considered unsuitable for this study by the investigator. |
Country | Name | City | State |
---|---|---|---|
China | Chinese PLA General Hospital | Beijing |
Lead Sponsor | Collaborator |
---|---|
Biotheus Inc. |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Objective Response Rate | Objective response rate (ORR) is the proportion of subjects with complete response (CR) or partial response (PR), based on RECIST v1.1 | Up to approximately 2 years | |
Primary | Treatment related adverse events (TRAEs) | The incidence and severity of TRAEs graded according to NCI-CTCAE v5.0 | Up to 30 days after last treatment | |
Secondary | Disease control rate (DCR) | DCR is defined as the proportion of subjects with CR, PR, or stable disease(SD) based on RECIST v1.1. | Up to approximately 2 years | |
Secondary | Duration of response (DoR) | DoR is defined as the duration from the first documentation of objective response to the first documented disease progression (based on RECIST v1.1) or death due to any cause, whichever occurs first | Up to approximately 2 years | |
Secondary | Progression free survival (PFS) | PFS is defined as the time from the start of treatment until the first documentation of disease progression or death due to any cause, whichever occurs first (based on RECIST v1.1) | Up to approximately 2 years | |
Secondary | Overall survival (OS) | OS is the time from the date of first dosing date to death due to any cause. | Up to approximately 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04464122 -
Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)
|
||
Active, not recruiting |
NCT03375320 -
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
|
Phase 3 | |
Active, not recruiting |
NCT03980925 -
Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) of the Gastroenteropancreatic (GEP) Tract or of Unknown (UK) Origin.
|
Phase 2 | |
Recruiting |
NCT02402244 -
Project: Every Child for Younger Patients With Cancer
|
||
Recruiting |
NCT05113355 -
Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm
|
Phase 2 | |
Terminated |
NCT03001349 -
68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors
|
Early Phase 1 | |
Completed |
NCT02399215 -
Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
|
Phase 2 | |
Recruiting |
NCT05165407 -
Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC
|
Phase 2 | |
Recruiting |
NCT06337760 -
YOUNg Adults With Gastro-inteSTinal (GI) and nEuroendocrine canceRs.
|
||
Recruiting |
NCT04927611 -
Single-cell Sequencing and Establishment of Models in Neuroendocrine Neoplasm
|
||
Active, not recruiting |
NCT01638533 -
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
|
Phase 1 | |
Recruiting |
NCT02817945 -
Dual SSTR2 and Integrin αvβ3 Targeting PET/CT Imaging
|
Early Phase 1 | |
Active, not recruiting |
NCT03950609 -
Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT04750954 -
Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors
|
Phase 1 | |
Active, not recruiting |
NCT02402920 -
Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer
|
Phase 1 | |
Not yet recruiting |
NCT04931446 -
Neuroendocrine Neoplasm Based on Multi-omics Integrated Analysis
|
||
Recruiting |
NCT06343428 -
Definition of a Multiparametric Prognostic and Predictive System of Classification of NET G3 Patients
|
||
Recruiting |
NCT04720391 -
Bone Metastases in neurOendocrine NEoplasms: naTural History, Prognostic Impact and Therapeutic Approach (MONET)
|
||
Recruiting |
NCT03734913 -
A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT03511768 -
A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms
|
Phase 1/Phase 2 |